ADAM17 and asthma: These findings supported the development of therapeutic strategies targeting the TNF-α signaling pathway (e.g. TNF-α antagonists) or ADAM17 activity (e.g. specific inhibitors), potentially restoring CD36-dependent phagocytosis and offering new therapeutic avenues for asthma.